SK Bioscience regained its license for its ‘SKYPneumo,’ the first-ever pneumococcal vaccine developed in Korea. This approval comes in less than a year since the company had withdrawn its license in October last year in the aftermath of losing a patent suit.

On the 4th, the Korean Ministry of Food and Drug Safety (MFDS) approved SK Bioscience’s 13-valent pneumococcal vaccine, ‘SKYPneumo prefilled syringe inj..'

The vaccine is used for infants six weeks to 6 months old and adults over 50 years of age to prevent pneumococcal disease. It was approved by demonstrating its non-inferiority to the existing vaccines in clinical trials. The MFDS designated the vaccine's re-examination period